Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma-Reference-Cited by-同舟云学术

Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma

Published:2023-08 Issue: Volume: Page:
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Reni Michele,Peretti Umberto,Macchini Marina,Orsi Giulia,Militello Annamaria,Briccolani Assunta,Falconi Massimo,Cascinu Stefano

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference30 articles.

1. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Von Hoff;N Engl J Med,2013

2. Groupe tumeurs digestives of unicancer; PRODIGE intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl J Med,2011

3. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial;Reni;Lancet Gastroenterol Hepatol,2018

4. NAPOLI-3: a randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC);Wainberg;J Clin Oncol,2023

5. Exploring chemotherapy holiday and drugs re‑challenge in advanced pancreatic cancer patients;Macchini;Cancer Chemother Pharmacol,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cyclophosphamide;Reactions Weekly;2024-08-10

2. Cyclophosphamide Pharmacogenomic Variation in Cancer Treatment and Its Effect on Bioactivation and Pharmacokinetics;Advances in Pharmacological and Pharmaceutical Sciences;2024-01